NCT06878170View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

January 30, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

RBM-001

To evaluate the safety and tolerability of the RBM-001 vaccination in healthy adults.

Trial Locations (1)

33143

QPS Miami, Miami

All Listed Sponsors
lead

Rock BioMedical, Inc.

INDUSTRY

NCT06878170 - A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter